Psychotropic drug-induced change of weight: a review
The purpose of this study is to give a systematic review of change of weight associated with commonly used psychotropic drugs. Mainly based on a MEDLINE-supported review until April 2005, data from clinical studies with antidepressants, anticonvulsants, mood stabilizers and neuroleptics were scanned...
Gespeichert in:
| Veröffentlicht in: | Fortschritte der Neurologie, Psychiatrie Psychiatrie, 2007-02, Vol.75 (2), p.65 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | ger |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 2 |
| container_start_page | 65 |
| container_title | Fortschritte der Neurologie, Psychiatrie |
| container_volume | 75 |
| creator | Drieling, T Biedermann, N C Schärer, L O Strobl, N Langosch, J M |
| description | The purpose of this study is to give a systematic review of change of weight associated with commonly used psychotropic drugs.
Mainly based on a MEDLINE-supported review until April 2005, data from clinical studies with antidepressants, anticonvulsants, mood stabilizers and neuroleptics were scanned for change of weight during treatment.
Among antidepressants amitryptiline and nortriptyline have the highest incidence of weight gain followed by imipramine. Maprotiline and mirtazapine have an intermediate weight increasing potential. SSRI (except paroxetine) and MAOI had no or only slight weight inducing effects. In contrary, bupropion was associated with weight reduction. Regarding mood stabilizers and anticonvulsants, a marked gain in weight with lithium and sodium valproate was reported frequently. With gabapentin and vigabatrin a slight to moderate gain in weight was found. Minor changes of weight were found with carbamazepine and lamotrigine. Treatment with topiramate and felbamate reportedly lead to weight loss. The atypical neuroleptics clozapine and olanzapine were frequently related to a strong gain in weight followed by risperidone. Quetiapine has intermediate effects. Stable weight was found with aripiprazole and ziprasidone. A gain in weight is less frequent with older/typical neuroleptics.
Beside some methodological restrictions like inconsistent information of weight changes (e. g. percent vs. mass) and the small sample of available long term studies, this review specifies the incidence of weight changes for commonly used psychotropic drugs and might be helpful to look for alternatives. |
| doi_str_mv | 10.1055/s-2005-919109 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_16586261</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16586261</sourcerecordid><originalsourceid>FETCH-LOGICAL-g164t-b8beda887bc0c8d3857766b712f6e9be85f87848bc1322d778050e96fca86a583</originalsourceid><addsrcrecordid>eNo1zrlOAzEQgGEXIBICJS3yCxhmvGt7TIciLikSFFBHPmYPRLKrPYjy9hRA9XeffiGuEG4QjLkdlQYwyqNH8CdiCU6DKrX3C3E-jp8AWHp0Z2KB1pDVFpeifBuPqemmoevbJPMw16rd5zlxlqkJ-5plV8kDt3Uz3ckgB_5u-XAhTqvwNfLlX1fi4_Hhff2sNq9PL-v7jarRlpOKFDkHIhcTJMoFGeesjQ51ZdlHJlORo5JiwkLr7ByBAfa2SoFsMFSsxPWv289xx3nbD-0uDMft_37xA9O1Q_s</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Psychotropic drug-induced change of weight: a review</title><source>MEDLINE</source><source>Thieme Connect Journals</source><creator>Drieling, T ; Biedermann, N C ; Schärer, L O ; Strobl, N ; Langosch, J M</creator><creatorcontrib>Drieling, T ; Biedermann, N C ; Schärer, L O ; Strobl, N ; Langosch, J M</creatorcontrib><description>The purpose of this study is to give a systematic review of change of weight associated with commonly used psychotropic drugs.
Mainly based on a MEDLINE-supported review until April 2005, data from clinical studies with antidepressants, anticonvulsants, mood stabilizers and neuroleptics were scanned for change of weight during treatment.
Among antidepressants amitryptiline and nortriptyline have the highest incidence of weight gain followed by imipramine. Maprotiline and mirtazapine have an intermediate weight increasing potential. SSRI (except paroxetine) and MAOI had no or only slight weight inducing effects. In contrary, bupropion was associated with weight reduction. Regarding mood stabilizers and anticonvulsants, a marked gain in weight with lithium and sodium valproate was reported frequently. With gabapentin and vigabatrin a slight to moderate gain in weight was found. Minor changes of weight were found with carbamazepine and lamotrigine. Treatment with topiramate and felbamate reportedly lead to weight loss. The atypical neuroleptics clozapine and olanzapine were frequently related to a strong gain in weight followed by risperidone. Quetiapine has intermediate effects. Stable weight was found with aripiprazole and ziprasidone. A gain in weight is less frequent with older/typical neuroleptics.
Beside some methodological restrictions like inconsistent information of weight changes (e. g. percent vs. mass) and the small sample of available long term studies, this review specifies the incidence of weight changes for commonly used psychotropic drugs and might be helpful to look for alternatives.</description><identifier>ISSN: 0720-4299</identifier><identifier>DOI: 10.1055/s-2005-919109</identifier><identifier>PMID: 16586261</identifier><language>ger</language><publisher>Germany</publisher><subject>Animals ; Anticonvulsants - adverse effects ; Antidepressive Agents, Tricyclic - adverse effects ; Antipsychotic Agents - adverse effects ; Humans ; Psychotropic Drugs - adverse effects ; Psychotropic Drugs - therapeutic use ; Serotonin Uptake Inhibitors - adverse effects ; Weight Gain - drug effects</subject><ispartof>Fortschritte der Neurologie, Psychiatrie, 2007-02, Vol.75 (2), p.65</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16586261$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Drieling, T</creatorcontrib><creatorcontrib>Biedermann, N C</creatorcontrib><creatorcontrib>Schärer, L O</creatorcontrib><creatorcontrib>Strobl, N</creatorcontrib><creatorcontrib>Langosch, J M</creatorcontrib><title>Psychotropic drug-induced change of weight: a review</title><title>Fortschritte der Neurologie, Psychiatrie</title><addtitle>Fortschr Neurol Psychiatr</addtitle><description>The purpose of this study is to give a systematic review of change of weight associated with commonly used psychotropic drugs.
Mainly based on a MEDLINE-supported review until April 2005, data from clinical studies with antidepressants, anticonvulsants, mood stabilizers and neuroleptics were scanned for change of weight during treatment.
Among antidepressants amitryptiline and nortriptyline have the highest incidence of weight gain followed by imipramine. Maprotiline and mirtazapine have an intermediate weight increasing potential. SSRI (except paroxetine) and MAOI had no or only slight weight inducing effects. In contrary, bupropion was associated with weight reduction. Regarding mood stabilizers and anticonvulsants, a marked gain in weight with lithium and sodium valproate was reported frequently. With gabapentin and vigabatrin a slight to moderate gain in weight was found. Minor changes of weight were found with carbamazepine and lamotrigine. Treatment with topiramate and felbamate reportedly lead to weight loss. The atypical neuroleptics clozapine and olanzapine were frequently related to a strong gain in weight followed by risperidone. Quetiapine has intermediate effects. Stable weight was found with aripiprazole and ziprasidone. A gain in weight is less frequent with older/typical neuroleptics.
Beside some methodological restrictions like inconsistent information of weight changes (e. g. percent vs. mass) and the small sample of available long term studies, this review specifies the incidence of weight changes for commonly used psychotropic drugs and might be helpful to look for alternatives.</description><subject>Animals</subject><subject>Anticonvulsants - adverse effects</subject><subject>Antidepressive Agents, Tricyclic - adverse effects</subject><subject>Antipsychotic Agents - adverse effects</subject><subject>Humans</subject><subject>Psychotropic Drugs - adverse effects</subject><subject>Psychotropic Drugs - therapeutic use</subject><subject>Serotonin Uptake Inhibitors - adverse effects</subject><subject>Weight Gain - drug effects</subject><issn>0720-4299</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1zrlOAzEQgGEXIBICJS3yCxhmvGt7TIciLikSFFBHPmYPRLKrPYjy9hRA9XeffiGuEG4QjLkdlQYwyqNH8CdiCU6DKrX3C3E-jp8AWHp0Z2KB1pDVFpeifBuPqemmoevbJPMw16rd5zlxlqkJ-5plV8kDt3Uz3ckgB_5u-XAhTqvwNfLlX1fi4_Hhff2sNq9PL-v7jarRlpOKFDkHIhcTJMoFGeesjQ51ZdlHJlORo5JiwkLr7ByBAfa2SoFsMFSsxPWv289xx3nbD-0uDMft_37xA9O1Q_s</recordid><startdate>20070201</startdate><enddate>20070201</enddate><creator>Drieling, T</creator><creator>Biedermann, N C</creator><creator>Schärer, L O</creator><creator>Strobl, N</creator><creator>Langosch, J M</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20070201</creationdate><title>Psychotropic drug-induced change of weight: a review</title><author>Drieling, T ; Biedermann, N C ; Schärer, L O ; Strobl, N ; Langosch, J M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g164t-b8beda887bc0c8d3857766b712f6e9be85f87848bc1322d778050e96fca86a583</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>ger</language><creationdate>2007</creationdate><topic>Animals</topic><topic>Anticonvulsants - adverse effects</topic><topic>Antidepressive Agents, Tricyclic - adverse effects</topic><topic>Antipsychotic Agents - adverse effects</topic><topic>Humans</topic><topic>Psychotropic Drugs - adverse effects</topic><topic>Psychotropic Drugs - therapeutic use</topic><topic>Serotonin Uptake Inhibitors - adverse effects</topic><topic>Weight Gain - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Drieling, T</creatorcontrib><creatorcontrib>Biedermann, N C</creatorcontrib><creatorcontrib>Schärer, L O</creatorcontrib><creatorcontrib>Strobl, N</creatorcontrib><creatorcontrib>Langosch, J M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Fortschritte der Neurologie, Psychiatrie</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Drieling, T</au><au>Biedermann, N C</au><au>Schärer, L O</au><au>Strobl, N</au><au>Langosch, J M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Psychotropic drug-induced change of weight: a review</atitle><jtitle>Fortschritte der Neurologie, Psychiatrie</jtitle><addtitle>Fortschr Neurol Psychiatr</addtitle><date>2007-02-01</date><risdate>2007</risdate><volume>75</volume><issue>2</issue><spage>65</spage><pages>65-</pages><issn>0720-4299</issn><abstract>The purpose of this study is to give a systematic review of change of weight associated with commonly used psychotropic drugs.
Mainly based on a MEDLINE-supported review until April 2005, data from clinical studies with antidepressants, anticonvulsants, mood stabilizers and neuroleptics were scanned for change of weight during treatment.
Among antidepressants amitryptiline and nortriptyline have the highest incidence of weight gain followed by imipramine. Maprotiline and mirtazapine have an intermediate weight increasing potential. SSRI (except paroxetine) and MAOI had no or only slight weight inducing effects. In contrary, bupropion was associated with weight reduction. Regarding mood stabilizers and anticonvulsants, a marked gain in weight with lithium and sodium valproate was reported frequently. With gabapentin and vigabatrin a slight to moderate gain in weight was found. Minor changes of weight were found with carbamazepine and lamotrigine. Treatment with topiramate and felbamate reportedly lead to weight loss. The atypical neuroleptics clozapine and olanzapine were frequently related to a strong gain in weight followed by risperidone. Quetiapine has intermediate effects. Stable weight was found with aripiprazole and ziprasidone. A gain in weight is less frequent with older/typical neuroleptics.
Beside some methodological restrictions like inconsistent information of weight changes (e. g. percent vs. mass) and the small sample of available long term studies, this review specifies the incidence of weight changes for commonly used psychotropic drugs and might be helpful to look for alternatives.</abstract><cop>Germany</cop><pmid>16586261</pmid><doi>10.1055/s-2005-919109</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0720-4299 |
| ispartof | Fortschritte der Neurologie, Psychiatrie, 2007-02, Vol.75 (2), p.65 |
| issn | 0720-4299 |
| language | ger |
| recordid | cdi_pubmed_primary_16586261 |
| source | MEDLINE; Thieme Connect Journals |
| subjects | Animals Anticonvulsants - adverse effects Antidepressive Agents, Tricyclic - adverse effects Antipsychotic Agents - adverse effects Humans Psychotropic Drugs - adverse effects Psychotropic Drugs - therapeutic use Serotonin Uptake Inhibitors - adverse effects Weight Gain - drug effects |
| title | Psychotropic drug-induced change of weight: a review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T18%3A54%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Psychotropic%20drug-induced%20change%20of%20weight:%20a%20review&rft.jtitle=Fortschritte%20der%20Neurologie,%20Psychiatrie&rft.au=Drieling,%20T&rft.date=2007-02-01&rft.volume=75&rft.issue=2&rft.spage=65&rft.pages=65-&rft.issn=0720-4299&rft_id=info:doi/10.1055/s-2005-919109&rft_dat=%3Cpubmed%3E16586261%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/16586261&rfr_iscdi=true |